Background: The generally dismal outcome of non-small-cell lung cancer (NSCLC) is believed to be associated with the systemic nature of this disease. In current practice, the decision to begin adjuvant chemotherapy in completely resected early stages is based on empirical criteria and has not yet been influenced by the presence of individual risk factors. Nonetheless, recent studies indicate that soluble tumor DNA is found in the serum and plasma of cancer patients, and microsatellite alterations have been identified in small-cell lung cancer and in head and neck neoplasms.
Introduction
As in many other countries, lung cancer has become the leading cause of cancer death for men in Spain [1] . Even in the subset of patients with a traditionally better outcome, those with surgical-pathologic stage I non-smallcell lung cancer (NSCLC), various sources report relapse rates of 30%-50% [2] . Evidence of the complex genetic basis underlying NSCLC progression and metastatic dissemination has been investigated in cohorts of patients for whom clinical correlation was available. Using such an approach, data from several recent studies highlight the fact that K-ras mutations, p53 abnormalities and c-erbB2 overexpression may have clinical implications. Moreover, measurement of prognostic markers is usually performed on primary tumors, which often results in a very limited view of the spectrum of biological properties that the cancer cells may exhibit. As our recent work in small-cell lung cancer (SCLC) has shown, a dynamic assessment of genetic abnormalities is feasible by targeting sera for p53 antibodies [3] . Ideally, followup studies ought to systematically pinpoint certain genetic disturbances in sera.
Previous studies have found that it is possible to detect free soluble DNA in serum and plasma. In fact, DNA levels were four times higher in cancer patients than in healthy individuals. N-ras gene mutations have been detected in plasma of patients with acute myelogenous leukemia and more recently, microsatellite alterations have been found in both the plasma of SCLC patients [4] and in the serum of head and neck cancer patients [5] . However, the presence of microsatellite alterations in the serum DNA of head and neck cancer patients has been hailed as a predictor of distant metastases [5] .
Patients and methods
We prospectively analyzed the presence of chromosome 3p microsatellite alterations in the serum of 22 completely resected NSCLC patients and selected four microsatellite markers at chromosome 3p because this chromosomal arm shows the highest percentage of loss of a Loss of the opposite allele to that found in the corresponding tumor tissue. Abbreviations: T -tumor DNA; S -serum DNA, ho -homozygous pattern; L -loss of heterozygosity; S -shift; SCC -squamous cell carcinoma; AC -adenocarcinoma; bAC -bronchoalveolar adenocarcinoma; LCC -large cell carcinoma; bo.met -bone metastasis; lu. metlung metastasis; br.met -brain metastasis; + -alive; DOD -died of disease; NED -no evidence of disease; LOF -lost to follow-up. -= heterozygous pattern without microsatellite alterations. The follow-up and outcome are indicated in months.
heterozygosity (LOH) in NSCLC and appears to harbor one or more tumor suppressor genes [6] . Lymphocytes, tumor tissue and corresponding serum were obtained from each patient. DNA from normal and tumor tissue was isolated using previously published methods. To obtain serum, blood specimens from each patient were incubated at 36 °C overnight and then centrifuged at low speed for 20 minutes The serum was stored at -80 °C before DNA extraction. Serum DNA was partially purified by a one-step extraction of phenol/chloroform and ethanol precipitation.
Normal, tumor and serum DNA were amplified by PCR. Primers for the microsatellite markers D3S1038, D3S1611, D3S1067 and D3S1284 were obtained from Research Genetics (Huntsville, AL, USA). PCR amplification and polyacrylamide gel electrophoresis was performed as described in previous studies [6, 7] . A negative control without DNA was included in every PCR reaction. DNA samples with microsatellite alterations were amplified at least twice to rule out artifacts or contaminants. Microsatellite alterations were defined as the presence of new alleles in the tumor or serum DNA compared with normal control (shifts) or as the complete or partial loss of a band (LOH) [6, 7] . Lymphocyte, serum and tumor DNA from each patient were analyzed in adjacent tracks. For LOH assessment, autoradiograph images were interpreted visually by comparing allelic intensities of normal and tumor DNA at the above-mentioned polymorphic loci. A reduction in signal intensity of > 50% in one of the two alleles was interpreted as LOH. To confirm these findings, the signal intensity of fragments was determined using a GS-690 Imaging Densitometer (BioRad, Richmond, CA), which provided quantitative verification of LOH.
Results
After correlating the microsatellite alterations of serum and tumor DNA of the 22 patients with the clinical data (see Table 1 ), 12 of the 22 (54%) tumor samples analyzed were found to have LOH in at least one marker. Furthermore, six patients (28%) exhibited microsatellite alterations, either a shift or LOH, in the serum DNA. This microsatellite alteration rate observed in the serum of NSCLC patients is similar to the 29% (6 of 21) reported previously in serum of head and neck cancer patients [5] , but lower than the 71% (15 of 21) observed in plasma of SCLC patients [4] . The NSCLC patients included in this study (except for patient 80) were staged as I-IIIA at the time of diagnosis and serum extraction. Of interest is the case of patient 80, a 41-year-old man diagnosed with TiN 2 M! lung adenocarcinoma with a single brain metastasis who underwent lobectomy after complete remission of the extrathoracic lesion following chemoradiotherapy; microsatellite alterations were found in this patient's serum DNA and in the tumor. The patient died of rapidly progressive disease a few months later.
LOH in both tumor and serum DNA at one or more microsatellite markers were found in patients 63, 74 and 80. Patient 74, classified as surgical-pathologic stage I, displayed tumor and serum LOH with all four microsatellite markers scanned. Furthermore, huge liver metastases and local relapse were discovered on computed tomography at one year. Moreover, patient 63 displayed an additional shift at D3S1284 marker in serum DNA, whereas LOH was detected in tumor tissue (Figure 1 ations (LOH and shift, respectively) in serum DNA alone ( Figure 1 , Table 1 ). Microsatellite alterations only in plasma DNA have been previously reported in SCLC [4] and hematological malignancies. Finally, the tumor tissue of patient 98 had LOH at D3S1284 and D3S1067 markers, but serum DNA retained both D3S1067 alleles and exhibited the loss of the opposite allele at D3S1284 to that of the tumor tissue ( Figure 1 ).
Discussion
As can be inferred from Table 1 , it is rather premature to draw prognostic implications from the serum findings, as the follow-up of these patients is still rather short. However, these observations agree with those of other investigators [4, 5] , demonstrating that microsatellite alterations or gene mutations in DNA serum or plasma can be different from those found in primary tumors. This phenomenon may well reflect the implication of several clones in some tumors as reported elsewhere [8] .
Much work needs to be done to clarify the presence of different DNA alterations in sera compared with those detected in the primary tumors. Serum DNA in cancer patients might stem either from cells that have begun to accumulate genetic alterations leading to metastasis formation or from circulating free DNA.
The ability to perform routine microsatellite analyses of sera will allow us to determine whether these genetic changes are actually useful molecular indicators of relapse, aggressiveness and therapy responsiveness in NSCLC.
